SEATTLE--(BUSINESS WIRE)--Blaze Bioscience, Inc., the Tumor Paint Company®, a biotechnology company focused on guided cancer therapy, announced today that interim clinical data from the company’s Phase 1 study of Tumor Paint BLZ-100 in adult patients with brain cancer will be presented at the 20th Annual Society for Neuro-Oncology (SNO) Scientific Meeting to be held November 19-22, 2015 in San Antonio, Texas.
Help employers find you! Check out all the jobs and post your resume.
